Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Drug Review Regulation

Tislelizumab & Tremelimumab Among Latest Filings In EU

  • News

Executive Summary

The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.

You may also be interested in...



New EU Filings

Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New EU Filings

Zolbetuximab, Astellas’ Claudin 18.2-targeting cancer drug, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

New EU Filings

Fruquintinib, Takeda/Hutchmed’s treatment for adult patients with previously treated metastatic colorectal cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Scrip

Topics

Related Companies

Tags:
Europe Drug Review Regulation
Latest Headlines

New EU Filings

Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package

WHO Seeks Feedback On Gaps In Current QA & GMP Guidelines

Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions

See All
UsernamePublicRestriction

Register

PS146106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By